Prospective randomized clinical trial to evaluate the optimal dose of 131I for remnant ablation in patients with differentiated thyroid carcinoma

@inproceedings{Bal1996ProspectiveRC,
  title={Prospective randomized clinical trial to evaluate the optimal dose of 131I for remnant ablation in patients with differentiated thyroid carcinoma},
  author={Chandrasekhar S Bal and Ajit Kumar Padhy and Suman Sekhar Jana and Gauri Shankar Pant and Asish Kumar Basu},
  year={1996}
}
BACKGROUND. Radioiodine has been used for more than a half-century to ablate thyroid remnants following thyroid surgery, but a single optimal dose has not been established. We designed a prospective randomized trial to determine the optimal dose of 131 I for remnant ablation. METHODS. Using a simple randomization technique, 149 patients with remnant thyroid were incorporated into 4 treatment groups. Twenty-seven of these patients were administered 25 to 34 millicurie (mCi) of 131 I (30 ± 1.5… CONTINUE READING

Similar Papers

Topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-10 OF 33 CITATIONS

Practical Management of Thyroid Cancer

  • Springer International Publishing
  • 2018
VIEW 10 EXCERPTS
CITES BACKGROUND & METHODS
HIGHLY INFLUENCED

Clinical review 128: Current approaches to primary therapy for papillary and follicular thyroid cancer.

  • The Journal of clinical endocrinology and metabolism
  • 2001
VIEW 3 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED